teclistamab,talquetamab,daratumumab,belantamab mafodotin
gsk,janssen,genmab
['bet', 'mmsm', 'monumental-1', 'daratumumab', 'teclistamab', 'belantamab', 'talquetamab', 'gsk']
congress | #ash22
ajai chari , describes phase ii results from the monumental-1 trial of sc talquetamab in rrmm. orr was 74.1% at 0.4 mg/kg qw dose (n=106/143), and 73.1% at 0.8 mg/kg q2w dose (n=106/145). crs was the most common ae at both doses. #mmsm 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma